Clinical Trial Update: Bioequivalence - Duodart Against Avodart & Omnic [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence trial comparing Duodart to Avodart and Omnic has completed in benign prostatic hyperplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• Avodart (dutasteride)
• Duodart (dutasteride/tamsulosin)
• Omnic (tamsulosin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Prostatic Hyperplasia | Phase 1 | Status: COMPLETED